COVID-19 vaccine effectiveness
(Randomized evidence)
Methods
Analyses are updated every two weeks
meta-COVID
Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:
Vaccine types
Vaccine efficacy and safety for vaccine vs placebo / no vaccine (forest plots)
Vaccine efficacy and safety for vaccine vs vaccine (forest plots)
Vaccine efficacy and safety against variants of concern (forest plots)
Vaccine efficacy, immunogenicity and safety of heterologous vs homologous vaccination (tables)
Vaccine efficacy, immunogenicity and safety of booster vs no booster (tables)
Vaccine efficacy, immunogenicity and safety of booster VS booster (tables)
Trials reports under extraction
In addition to the below included trials, we have included and presently extracting 21 new vaccine randomized trials
Description of primary studies
In this table, we report the main characteristics of the COVID-19 vaccine candidates from RCTs identified, in addition to the overall risk of bias assessment.
As of January 2022, we will extract and present results of early phase trials only when the dose has been selected. Results from phase 1-2 studies are included in forest plots for the chosen vaccine dose and schedule only.
Search studies
Your research ==> Vaccine name: 1273
Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
---|---|---|---|---|---|---|---|---|
Intervention 1 | Intervention 2 | |||||||
NCT04649151 ModernaTX Ali K, N Engl J Med, 2021 Full text Commentary |
RNA based vaccine |
mRNA-1273 |
Placebo |
RCTPhase 2-3 | Healthy adolescents in 26 centers in the USA | N=3732 |
Some concerns Details |
|
EudraCT 2021-002348-57 Pfizer-BioNTech; Moderna; Oxford-AstraZeneca Bonelli M, Ann Rheum Dis , 2022 Full text Commentary |
Heterologous booster |
Boost ChAdOx1/prime vaccination BNT162b2 or mRNA-1273 |
Boost BNT162b2 or mRNA-1273/prime vaccination BNT162b2 or mRNA-1273 |
RCT2 | Adults under current rituximab therapy who did not develop humoral response against SARS-CoV-2 after their standard vaccination with Biontech/Pfizer or Moderna in a single center in Austria | N=60 |
Some concerns Details |
|
NCT04796896 ModernaTX Creech CB, N Engl J Med, 2022 KidCOVE Full text Commentary |
RNA based vaccine |
mRNA-1273 (50 mcg D0/28) |
Placebo |
RCTPhase 2-3 | Children aged 6-11 years, healthy or with stable chronic conditions and no known recent history of COVID-19 infection, at 87 centers in Canada and USA. | N=4016 |
Some concerns Details |
|
NCT04470427 ModernaTX El Sahly HM, N Engl J Med, 2021 COVE Full text Commentary |
RNA based vaccine |
mRNA-1273 100 mcg D1/28 |
Placebo D1/28 |
RCTPhase 3 | Healthy adults with no known history of SARS-CoV-2 infection in 99 centers in the US | N=30415 |
Some concerns Details |
|
NCT04885907 ModernaTX Hall VG, N Engl J Med, 2021 Full text Commentary Commentary |
RNA based vaccine |
mRNA-1273 |
Placebo |
RCTPhase 4 | Solid organ transplant recipients with no previous diagnosis of COVID-19 who has previously received two doses of mRNA-1273 at a single center in Canada | N=120 |
Some concerns Details |
|
NCT04900467; EudraCT: 2021-002174-52 Moderna;Pfizer/BioNTech Janssen C, EClinicalMedicine, 2022 Full text Full text Commentary |
Heterologous vaccination scheme |
1 dose BNT162b2/1 dose mRNA-1273 1 dose mRNA-1273 /1 dose BNT162b2 |
2 doses BNT162b2 2 doses mRNA-1273 |
RCTPhase 2 | Adults with no known or suspected history of SARS-CoV-2 infection at 17 centers in France. | N=414 |
Some concerns Details |
|
NCT04962906; NCT05027672 Gamaleya Research Institute, AstraZeneca+University of Oxford;Moderna;Sinopharm Macchia A, Lancet Reg Health Am, 2022 Full text Commentary |
Non replicating viral vector |
Gam-COVID-Vac rAd26-S |
Gam-COVID-Vac rAd26-S/BBIBP-CorV |
RCTPhase 2 | Adults who had received the first dose (rAd26) of the Sputnik V vaccine at least 30 days earlier and no history of SARS-CoV-2 at a single centre in Argentina | N=540 |
Some concerns Details |
|
NCT04677660 ModernaTX Masuda T, Vaccine, 2022 a Full text Commentary |
RNA based vaccine |
mRNA-1273 |
Placebo |
RCTPhase 1-2 | Healthy adults aged ≥ 20 years with no known history/risk of SARS-CoV-2 infection at 2 centers in Japan. | N=200 |
Some concerns Details |
|
ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A, Lancet, 2021 f COV-BOOST Full text Commentary |
Heterologous booster |
BNT162b2/boost mRNA1273 BNT162b2/boost CVnCov BNT162b2/boost BNT162b2 half dose |
BNT162b2/Placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N=439 |
Some concerns Details |
|
ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A, Lancet, 2021 d COV-BOOST Full text Commentary |
RNA based vaccine |
BNT162b2/boost BNT162b2 BNT162b2/boost VLA2001 BNT162b2/boost VLA2001 half dose BNT162b2/boost Ad26.COV2.S |
BNT162b2/Placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N=545 |
Some concerns Details |
|
ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A , Lancet, 2021 a COV-BOOST Full text Commentary |
Non replicating viral vector |
ChadOx1/boost ChadOx1 ChadOx1/boost Novavax ChadOx1/boost Novavax half dose |
ChadOx1/Placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N=443 |
Some concerns Details |
|
ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A, Lancet, 2021 b COV-BOOST Full text Commentary |
Heterologous booster |
BNT162b2/ boost ChAdOx1 BNT162b2/boost Novavax BNT162b2/boost Novavax half dose |
BNT162b2/ Placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N=453 |
Some concerns Details |
|
ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A, Lancet, 2021 e COV-BOOST Full text Commentary |
Heterologous booster |
ChadOx1/boost mRNA1273 ChadOx1/boost CVnCov ChadOx1/boost BNT162b2 half dose |
ChadOx1/Placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N=462 |
Some concerns Details |
|
ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A, Lancet, 2021 c COV-BOOST Full text Commentary |
Heterologous booster |
ChadOx1/boost BNT162b2 ChadOx1/boost VLA2001 ChadOx1/boost VLA2001 half dose ChadOx1/boost Ad26.COV2.S |
ChadOx1/Placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N=541 |
Some concerns Details |
|
ISRCTN73765130 ; EudraCT 2021-002175-19 Pfizer/BioNTech;ModernaTX Munro APS, Lancet Infect Dis, 2022 COV-BOOST Full text Commentary Commentary (22)00282-1/fulltext |
RNA based vaccine |
BNT162b2 + 2 booster doses BNT162b2 ChadOx1 + boost 2 doses BNT162b2 |
BNT162b2 + booster dose BNT162b2+ 2nd booster half mRNA-1273 ChadOx1 + boost 1 dose BNT162b2+ half dose m-RNA 1273 |
RCTPhase 2 | Healthy adults aged 30 years or over, including elderly and those with well controlled or mild-moderate comorbidity, who had received a 2-dose primary schedule of either BNT162b2 or ChAdOx1 and a BNT162b2 booster at 18 centers in the UK | N=166 |
Some concerns Details |
|
NCT05142319 Pfizer/BioNTech+Fosun Pharma; ModernaTX Poh XY, Clin. Infect. Dis., 2022 PRIBIVAC Full text Commentary |
RNA based vaccine |
Boost mRNA-1273 after prime vaccination with BNT162b2 |
Boost BNT162b2 after prime vaccination with BNT162b2 |
RCT3 | Adults at a single center in Singapore with no previous history of COVID-19 who had received a primary series of BTN162b2 at least 6 months previously | N=100 |
Some concerns Details |
|
EudraCT021-002927-39 Pfizer/BioNTech+Fosun Pharma/Moderna/Janssen Pharmaceutical Companies Reindl-Schwaighofer R, JAMA, 2021 Full text Commentary Commentary |
RNA based vaccine |
mRNA-1273 or BNT162b2/homologous booster |
mRNAorBNT/Ad26COVS1 booster |
RCTPhase 2 | Adult kidney transplant recipients with no history of COVID-19 infection and without an antibody response 4 weeks after a 2-dose mRNA vaccine schedule at a single center in Austria. | N=201 |
Some concerns Details |
|
NCT04927936 Janssen Pharmaceutical;Moderna ;Pfizer/BionTech+Fosun Pharma Sablerolles R, N Engl J Med, 2022 Full text Commentary |
Non replicating viral vector |
Ad26.COV2.S/m-RNA-1273 Ad26.COV2.S/Ad26.COV2.S Ad26.COV2.S/Ad26.COV2.S |
Ad26.COV2.S/BNT162b2 Ad26.COV2.S/m-RNA-1273 Ad26.COV2.S/BNT162b2 |
RCTPhase 3 | Healthcare workers aged 18-65 years, without severe comorbidities, and no known history of SARS-CoV-2 infection who received a single Ad26.COV2.S primary vaccination at 4 centers in the Netherlands. | N=461 |
Some concerns Details |
|
NCT04805125 Pfizer/BioNTech+Fosun Pharma; ModernaTX Speich B, Clin. Infect. Dis., 2022 Full text Commentary Commentary |
RNA based vaccine |
BNT162b2 |
mRNA-1273 |
RCTPhase 3 | Adult patients living with HIV (PLWH) or solid organ transplant recipients who were SARS-CoV-2 infection-free for the last 3 months in 3 centres in Switzerland. | N=430 |
Some concerns Details |
|
ISRCTN27841311; EudraCT 2021-001275-16 Pfizer BioNTech + Fosun Pharma / Novavax / Moderna + NIAID Stuart A, Lancet, 2021 b Com-COV2 Full text Commentary Commentary |
Protein subunit |
1 dose BNT162b2 followed by 1 dose NVX-CoV2373 1 dose BNT162b2 followed by 1 dose mRNA-1273 |
2 doses BNT162b2 |
RCTPhase 2 | Adults over 50 years previously vaccinated with one dose of BNT162b2 at 9 centres in the UK | N=532 |
Some concerns Details |
|
ISRCTN27841311; EudraCT 2021-001275-16 AstraZeneca + University of Oxford / Novavax / Moderna + NIAID Stuart A, Lancet, 2021 a Com-COV2 Full text Commentary Commentary |
Protein subunit |
1 dose ChAdOx1 followed by 1 dose NVX-CoV2373 1 dose ChAdOx1 followed by 1 dose mRNA-1273 |
2 doses ChAdOx1 |
RCTPhase 2 | Healthy adults over 50 years previously vaccinated with one dose of ChAdOx1 nCoV-19 in 9 centres in the UK | N=540 |
Some concerns Details |